NuMedii discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii, consists of hundreds of millions of raw human, biological, pharmacological and clinical data points that the company has normalized and annotated. The company integrates these data with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases.

NuMedii discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii, consists of hundreds of millions of raw human, biological, pharmacological and clinical data points that the company has normalized and annotated. The company integrates these data with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases.

Cyclica operates in the exciting intersection of Technology and Life Sciences/Healthcare. Cyclica enhances drug discovery by harnessing big data and predictive analytics through it's patented cloud based platform, Ligand Express™ (www.ligandexpress.com). Traditional design of small molecule therapies has focused on specific, disease-associated protein targets which has led to the development of many breakthrough medicines. However, once a drug enters the body it interacts with dozens, if not hundreds, of proteins before it is excreted. These off-target interactions can represent threats to the safety of a drug, or potential repurposing opportunities. Cyclica harnesses biophysics, biological data, and artificial intelligence (AI) to help pharmaceutical companies navigate the drug discovery pipeline by assessing the safety and efficacy of drugs. Whether pre-clinical, clinical, or FDA approved, Cyclica's patented, drug-centric, structure-based and AI-augmented platform, Ligand Express™ , offers novel insight and analysis into a drugs’ poylpharmacology (i.e. all the proteins a drug interacts with). By focusing on a small molecule structure and its polypharmacological profile, we distinguish ourselves with virtual screening technologies that are specific for a protein structure. We further augment our structural information with AI to drive our biophysical simulations. Learn more through a short video: https://www.youtube.com/watch?v=pYtLKSZB-r0 or by visiting our website at https://cyclicarx.com/ligandexpress/. Our publications, validation notes, and case studies can be found here: https://cyclicarx.com/documentation/

Cyclica operates in the exciting intersection of Technology and Life Sciences/Healthcare. Cyclica enhances drug discovery by harnessing big data and predictive analytics through it's patented cloud based platform, Ligand Express™ (www.ligandexpress.com). Traditional design of small molecule therapies has focused on specific, disease-associated protein targets which has led to the development of many breakthrough medicines. However, once a drug enters the body it interacts with dozens, if not hundreds, of proteins before it is excreted. These off-target interactions can represent threats to the safety of a drug, or potential repurposing opportunities. Cyclica harnesses biophysics, biological data, and artificial intelligence (AI) to help pharmaceutical companies navigate the drug discovery pipeline by assessing the safety and efficacy of drugs. Whether pre-clinical, clinical, or FDA approved, Cyclica's patented, drug-centric, structure-based and AI-augmented platform, Ligand Express™ , offers novel insight and analysis into a drugs’ poylpharmacology (i.e. all the proteins a drug interacts with). By focusing on a small molecule structure and its polypharmacological profile, we distinguish ourselves with virtual screening technologies that are specific for a protein structure. We further augment our structural information with AI to drive our biophysical simulations. Learn more through a short video: https://www.youtube.com/watch?v=pYtLKSZB-r0 or by visiting our website at https://cyclicarx.com/ligandexpress/. Our publications, validation notes, and case studies can be found here: https://cyclicarx.com/documentation/